SCHEMBL14925307

SCHEMBL14925307

CCOC(=O)CCc1c(C)c2cc(C)c(O)cc2oc1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.71
ALDH1A1 P00352 11/20 0.71
HPGD P15428 8/20 0.71
HSD17B10 Q99714 8/20 0.71
CASP1 P29466 4/20 0.71
CASP7 P55210 4/20 0.71
GAA P10253 3/20 0.71
GLA P06280 3/20 0.71
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
TSHR P16473 3/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 3/20 0.50
NPSR1 Q6W5P4 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
THRB P10828 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HSD17B3 P37058 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7798964 0.93 KDM4E (0.74) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14925274 0.89 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14925290 0.88 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14930177 0.87 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14916213 0.86 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL2555949 0.83 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL30406107 0.83 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL2554744 0.83 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14925310 0.82 KDM4E (0.61) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL20478129 0.82 KDM4E (0.61) KDM4EALDH1A1HPGDHSD17B10CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409276-B1 IRE-1A INHIBITORS FOSUN ORINOVE PHARMATECH INC (CN) 2020-12-30 EP disclosed
US-9867803-B2 IRE-1α inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-16 US disclosed
US-20170326104-A1 IRE-1ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-11-16 US disclosed
US-9693992-B2 IRE-1α inhibitors MANNKIND CORPORATION (US) 2017-07-04 US disclosed
US-9040714-B2 IRE-1α inhibitors MANNKIND CORPORATION (US) 2015-05-26 US disclosed
US-20150141424-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2015-05-21 US disclosed
US-20130116247-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141424-A1 IRE-1alpha INHIBITORS ERN1, XBP1, ERN2 KDM4E 2950/4885ALDH1A1 2024/4885HPGD 649/4885
US-20170326104-A1 IRE-1ALPHA INHIBITORS ERN1, XBP1, ERN2 KDM4E 2950/4885ALDH1A1 2024/4885HPGD 649/4885
US-20130116247-A1 IRE-1alpha INHIBITORS ERN1, XBP1, ERN2 KDM4E 2975/4885ALDH1A1 2036/4885HPGD 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.